246 related articles for article (PubMed ID: 23036267)
1. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review.
Nittur N; Konofal E; Dauvilliers Y; Franco P; Leu-Semenescu S; Cock VC; Inocente CO; Bayard S; Scholtz S; Lecendreux M; Arnulf I
Sleep Med; 2013 Jan; 14(1):30-6. PubMed ID: 23036267
[TBL] [Abstract][Full Text] [Related]
2. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy.
Lavault S; Dauvilliers Y; Drouot X; Leu-Semenescu S; Golmard JL; Lecendreux M; Franco P; Arnulf I
Sleep Med; 2011 Jun; 12(6):550-6. PubMed ID: 21576035
[TBL] [Abstract][Full Text] [Related]
3. Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study.
Mansukhani MP; Kotagal S
Sleep Med; 2012 Jun; 13(6):606-10. PubMed ID: 22445591
[TBL] [Abstract][Full Text] [Related]
4. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
[TBL] [Abstract][Full Text] [Related]
5. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review.
Leu-Semenescu S; Nittur N; Golmard JL; Arnulf I
Sleep Med; 2014 Jun; 15(6):681-7. PubMed ID: 24854887
[TBL] [Abstract][Full Text] [Related]
6. Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
Leu-Semenescu S; Louis P; Arnulf I
Sleep Med; 2016 Jan; 17():38-44. PubMed ID: 26847972
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRB1( *)1501/DQB1( *)0602 finding.
Sasai T; Inoue Y; Komada Y; Sugiura T; Matsushima E
Sleep Med; 2009 Oct; 10(9):961-6. PubMed ID: 19410508
[TBL] [Abstract][Full Text] [Related]
8. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience.
Poryazova R; Tartarotti S; Khatami R; Baumann CR; Valko P; Kallweit U; Werth E; Bassetti CL
Eur Neurol; 2011; 65(3):175-82. PubMed ID: 21389728
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.
Ann Neurol; 1998 Jan; 43(1):88-97. PubMed ID: 9450772
[TBL] [Abstract][Full Text] [Related]
10. Psychological health in central hypersomnias: the French Harmony study.
Dauvilliers Y; Paquereau J; Bastuji H; Drouot X; Weil JS; Viot-Blanc V
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):636-41. PubMed ID: 19211597
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatments for narcolepsy and its related disorders.
Nishino S; Okuro M
Expert Opin Emerg Drugs; 2010 Mar; 15(1):139-58. PubMed ID: 20166851
[TBL] [Abstract][Full Text] [Related]
12. Therapies for narcolepsy with or without cataplexy: evidence-based review.
Keam S; Walker MC
Curr Opin Neurol; 2007 Dec; 20(6):699-703. PubMed ID: 17992092
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of mazindol on narcolepsy.
Iijima S; Sugita Y; Teshima Y; Hishikawa Y
Sleep; 1986; 9(1 Pt 2):265-8. PubMed ID: 3704452
[TBL] [Abstract][Full Text] [Related]
14. Narcolepsy: treatment issues.
Roth T
J Clin Psychiatry; 2007; 68 Suppl 13():16-9. PubMed ID: 18078361
[TBL] [Abstract][Full Text] [Related]
15. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
Morgenthaler TI; Kapur VK; Brown T; Swick TJ; Alessi C; Aurora RN; Boehlecke B; Chesson AL; Friedman L; Maganti R; Owens J; Pancer J; Zak R;
Sleep; 2007 Dec; 30(12):1705-11. PubMed ID: 18246980
[TBL] [Abstract][Full Text] [Related]
16. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Huang YS; Guilleminault C
Pediatr Neurol; 2009 Jul; 41(1):9-16. PubMed ID: 19520267
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
Shelton J; Nishino S; Vaught J; Dement WC; Mignot E
Sleep; 1995 Dec; 18(10):817-26. PubMed ID: 8746387
[TBL] [Abstract][Full Text] [Related]
18. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
[TBL] [Abstract][Full Text] [Related]
19. Amphetamine, mazindol, and fencamfamin in narcolepsy.
Shindler J; Schachter M; Brincat S; Parkes JD
Br Med J (Clin Res Ed); 1985 Apr; 290(6476):1167-70. PubMed ID: 2859077
[TBL] [Abstract][Full Text] [Related]
20. Use of modafinil in the treatment of narcolepsy: a long term follow-up study.
Besset A; Chetrit M; Carlander B; Billiard M
Neurophysiol Clin; 1996; 26(1):60-6. PubMed ID: 8657099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
